{
  "image_filename": "figure_p3_det_2_002.png",
  "image_path": "Zimmerman_et_al.__2023_/extracted/figures/figure_p3_det_2_002.png",
  "image_type": "Figure",
  "page_number": 3,
  "block_id": "det_2_002",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Flowchart showing the number of participants in primary analyses: recombinant quadrivalent influenza vaccine (RIV4) n=3,047, standard-dose quadrivalent influenza vaccine (SD-IIV4) n=862, and unvaccinated n=8,878; after exclusions RIV4 n=291, SD-IIV4 n=114, unvaccinated n=1,398. The figure does not specify Fluarix by name, only generic SD-IIV4 comparator, therefore it does not support the claim that Flublok (RIV4) was evaluated specifically against Fluarix.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Flowchart showing the number of participants in primary analyses: recombinant quadrivalent influenza vaccine (RIV4) n=3,047, standard-dose quadrivalent influenza vaccine (SD-IIV4) n=862, and unvaccinated n=8,878; after exclusions RIV4 n=291, SD-IIV4 n=114, unvaccinated n=1,398.",
    "evidence_found": null,
    "reasoning": "The figure does not specify Fluarix by name, only generic SD-IIV4 comparator, therefore it does not support the claim that Flublok (RIV4) was evaluated specifically against Fluarix.",
    "confidence_notes": null
  }
}